Diabetes Dialogue: GLP-1 RA Shortage & ADA/KDIGO Recommendations

Podcast

The month of October brought new twists to familiar themes in the world of diabetes management.

Among the most common and unfortunate realities for people with diabetes is difficulty with access to insulin. In recent weeks, a reported shortage of GLP-1 receptor agonists is further burdening the community. And, although updated guidance for diabetes management is published frequently, a new consensus report for the management of chronic kidney disease in diabetes from a pair of major organizations published earlier this month is drawing additional attention to a growing issue with major public health implications.

Published on October 3, the American Diabetes Association and Kidney Disease: Improving Global Outcomes (KDIGO) joint consensus report on diabetes management in CKD provides clinicians with an overview of the organizations' alignment in areas such as screening and diagnosis, glycemic monitoring, lifestyle therapies, treatment goals, and pharmacologic management.

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, take the time to discuss the ongoing GLP-1 RA shortage, whether or not celebrities using these agents for weight loss is a real issue in the community, and their top takeaways from the ADA/KDIGO consensus report.

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.

Related Videos
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Hematopoietic Stem Cell Transplantation Improves Pediatric SCD Outcomes | Image Credit: Scott Graham/Unsplash
Andrew Talal, MD | Credit: University at Buffalo
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Albert Foa, MD, PhD | Credit: HCPLive
Veraprapas Kittipibul, MD | Credit: X.com
© 2024 MJH Life Sciences

All rights reserved.